Nykode Therapeutics As

Greetings and welcome to the NICO Therapeutics Third Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Chief Executive Officer Michael Ensign. Thank you. You may begin.

Thank you very much. And also from our side, a warm welcome to all participants joining here, both from Europe and the early birds from the U.S. Start out with a quick note on the forward-looking statement. We assume you're all familiar with that. So on that note, we'll move forward. With me today here at this third quarter call, I'm very pleased to have Arne Fredriksen, our co-founder and chief business officer, as well as Arne Grovin, our chief financial officer, and Michael Ingsie. CEO of Nycode. A quick introduction to those of you who are new to Nycode. Nycode is a Norwegian-based immunotherapy company. We're entirely focused to building the leading immunotherapy company, and we're focused on a dual strategy, advancing our portfolio, which consists of a good mix of in-house programs and partner programs through development stages towards the market, while at the same time investing in broadening out the application and the potential of our platform. We have also focused on validating and de-risking the company through clinical data, partnerships, a broad application, as I mentioned, and a solid cash position. So we have taken four different compounds all based on our core platform into clinical development. We have consistently shown, through these clinical trials, the ability to raise a strong T cell response, and in particular, a strong broad CD8 kilo T cell response. We have also consistently shown that the technology is well-tolerated and safe for the patient, both as a monotherapy and in combination with various other anti-cancer drugs. We entered three partnerships with top-tier US-based biopharmaceutical companies, built the organization to scale. We're now more than 150 employees in the company or offices in Oslo and Copenhagen and Denmark and we've also focused on internalizing core competencies in the early research and in your monitoring area. As I mentioned, the platform's potential is already now used across a number of different tumor types, both in oncology, and we've also taken it into infectious diseases, and we've announced that we see a potential to move this into autoimmune diseases also. We just today reported a strong cash position, $212 million at the end of third quarter, and the company is listed on the Oslo Stock Exchange. So it's been another busy quarter and this one in terms of clinical trials. So we started out by reporting the exciting interim results from our T-cell focused Cov2 vaccine that was followed by the positive immunogenicity results from our phase one trial with Levitoneo, our individualized cancer therapy that we are developing together with Genentech. And finally, we reported the additional efficacy analysis from our Phase II trial with BP1016, which is right now investigated in patients with advanced cervical cancer. And our data fraction will take us into a deep dive on these data in a few minutes. On the finance side, as we mentioned, we continue to have a very strong cash position of $212 million U.S. dollars. And we were recently included in two of the important indexes on the Oslo Stock Exchange. We've grown the company now up to 153 employees as of today. And with those words, I'm going to hand over to Auneide.

Thank you, Michael. Yes, so you have to change the slides. Yes.